 Xianzhong Meng
Concepts (401)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Valve | 40 | 2023 | 401 | 11.990 |
Why?
| | Aortic Valve Stenosis | 30 | 2023 | 295 | 8.790 |
Why?
| | Toll-Like Receptor 4 | 32 | 2021 | 330 | 6.520 |
Why?
| | Calcinosis | 22 | 2022 | 282 | 6.520 |
Why?
| | Osteogenesis | 17 | 2022 | 213 | 5.130 |
Why?
| | Toll-Like Receptor 2 | 12 | 2022 | 127 | 3.750 |
Why?
| | NF-kappa B | 25 | 2022 | 670 | 3.270 |
Why?
| | Intercellular Adhesion Molecule-1 | 17 | 2022 | 175 | 2.890 |
Why?
| | Bone Morphogenetic Protein 2 | 14 | 2018 | 90 | 2.640 |
Why?
| | Cells, Cultured | 37 | 2023 | 4077 | 2.300 |
Why?
| | Myocardium | 12 | 2017 | 970 | 2.100 |
Why?
| | Monocytes | 3 | 2022 | 513 | 1.970 |
Why?
| | Heart Valve Diseases | 5 | 2020 | 135 | 1.930 |
Why?
| | Glucuronidase | 3 | 2020 | 48 | 1.920 |
Why?
| | Interleukin-1 | 6 | 2023 | 980 | 1.850 |
Why?
| | Endotoxemia | 7 | 2017 | 93 | 1.790 |
Why?
| | Myocardial Reperfusion Injury | 5 | 2015 | 105 | 1.640 |
Why?
| | Lipoproteins, LDL | 5 | 2017 | 138 | 1.630 |
Why?
| | Biglycan | 4 | 2017 | 11 | 1.610 |
Why?
| | Up-Regulation | 14 | 2020 | 872 | 1.580 |
Why?
| | Signal Transduction | 30 | 2023 | 4709 | 1.460 |
Why?
| | Reperfusion Injury | 8 | 2022 | 276 | 1.380 |
Why?
| | Interleukins | 4 | 2022 | 242 | 1.350 |
Why?
| | Receptor, Notch1 | 3 | 2014 | 65 | 1.350 |
Why?
| | Neurotrophin 3 | 2 | 2020 | 15 | 1.340 |
Why?
| | Matrilin Proteins | 4 | 2022 | 14 | 1.330 |
Why?
| | Proto-Oncogene Proteins c-akt | 5 | 2020 | 420 | 1.310 |
Why?
| | Myofibroblasts | 4 | 2018 | 120 | 1.250 |
Why?
| | Inflammation Mediators | 4 | 2022 | 502 | 1.220 |
Why?
| | Lipopolysaccharides | 17 | 2020 | 870 | 1.180 |
Why?
| | Heart | 8 | 2017 | 631 | 1.180 |
Why?
| | Tumor Necrosis Factor-alpha | 9 | 2013 | 1171 | 1.170 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2017 | 164 | 1.140 |
Why?
| | Matrix Metalloproteinases | 2 | 2017 | 90 | 1.050 |
Why?
| | Coronary Vessels | 2 | 2021 | 233 | 1.040 |
Why?
| | Down-Regulation | 6 | 2020 | 627 | 1.040 |
Why?
| | Vascular Calcification | 2 | 2017 | 123 | 1.030 |
Why?
| | Esophageal Neoplasms | 10 | 2022 | 281 | 1.010 |
Why?
| | Collagen | 4 | 2022 | 433 | 1.010 |
Why?
| | Chemokine CCL2 | 5 | 2017 | 126 | 1.000 |
Why?
| | Recombinant Proteins | 10 | 2023 | 1308 | 0.970 |
Why?
| | Spinal Cord Ischemia | 8 | 2018 | 78 | 0.950 |
Why?
| | Inflammation | 10 | 2021 | 2566 | 0.940 |
Why?
| | MicroRNAs | 3 | 2019 | 637 | 0.920 |
Why?
| | Endothelial Cells | 3 | 2021 | 732 | 0.900 |
Why?
| | Extracellular Matrix Proteins | 3 | 2021 | 133 | 0.860 |
Why?
| | Chemokines | 4 | 2015 | 230 | 0.830 |
Why?
| | Heart Diseases | 2 | 2022 | 341 | 0.820 |
Why?
| | Anti-Inflammatory Agents | 3 | 2023 | 465 | 0.810 |
Why?
| | Group II Phospholipases A2 | 7 | 2020 | 23 | 0.800 |
Why?
| | Receptor, trkA | 2 | 2020 | 20 | 0.780 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 4 | 2020 | 173 | 0.780 |
Why?
| | Adenocarcinoma | 10 | 2022 | 812 | 0.780 |
Why?
| | HSP70 Heat-Shock Proteins | 4 | 2017 | 74 | 0.780 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 4 | 2021 | 154 | 0.760 |
Why?
| | Mice, Inbred C57BL | 22 | 2022 | 4908 | 0.760 |
Why?
| | Disease Susceptibility | 1 | 2022 | 331 | 0.720 |
Why?
| | Osteoblasts | 2 | 2017 | 115 | 0.710 |
Why?
| | Phospholipases A2, Secretory | 6 | 2019 | 27 | 0.700 |
Why?
| | Animals | 47 | 2023 | 33381 | 0.690 |
Why?
| | Alkaline Phosphatase | 7 | 2019 | 157 | 0.690 |
Why?
| | Aging | 3 | 2022 | 1670 | 0.680 |
Why?
| | HSC70 Heat-Shock Proteins | 2 | 2009 | 6 | 0.680 |
Why?
| | Toll-Like Receptor 3 | 2 | 2017 | 31 | 0.670 |
Why?
| | Mice | 36 | 2023 | 15520 | 0.660 |
Why?
| | Myeloid Differentiation Factor 88 | 3 | 2020 | 95 | 0.660 |
Why?
| | Gastroesophageal Reflux | 6 | 2022 | 248 | 0.660 |
Why?
| | Male | 50 | 2022 | 57801 | 0.660 |
Why?
| | Myocardial Contraction | 3 | 2008 | 339 | 0.640 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2022 | 387 | 0.630 |
Why?
| | Humans | 68 | 2023 | 118974 | 0.620 |
Why?
| | Middle Aged | 25 | 2022 | 27617 | 0.620 |
Why?
| | Barrett Esophagus | 5 | 2022 | 154 | 0.620 |
Why?
| | ADAMTS5 Protein | 1 | 2017 | 7 | 0.620 |
Why?
| | Neutrophil Infiltration | 3 | 2009 | 97 | 0.600 |
Why?
| | Heart Defects, Congenital | 3 | 2020 | 703 | 0.600 |
Why?
| | Cell Transdifferentiation | 1 | 2017 | 32 | 0.600 |
Why?
| | SOX9 Transcription Factor | 1 | 2017 | 24 | 0.600 |
Why?
| | Cyclin D1 | 1 | 2017 | 61 | 0.600 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 7 | 2023 | 52 | 0.590 |
Why?
| | HSP27 Heat-Shock Proteins | 2 | 2014 | 14 | 0.590 |
Why?
| | Lysophosphatidylcholines | 1 | 2017 | 36 | 0.590 |
Why?
| | RNA, Double-Stranded | 1 | 2017 | 46 | 0.580 |
Why?
| | Cell Proliferation | 11 | 2020 | 2275 | 0.570 |
Why?
| | Phosphates | 1 | 2017 | 167 | 0.550 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 539 | 0.550 |
Why?
| | RNA Interference | 6 | 2017 | 460 | 0.540 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 4 | 2022 | 42 | 0.540 |
Why?
| | Immunity, Innate | 3 | 2019 | 745 | 0.530 |
Why?
| | Aged | 16 | 2019 | 19657 | 0.520 |
Why?
| | Extracellular Space | 3 | 2010 | 127 | 0.520 |
Why?
| | Enzyme Inhibitors | 6 | 2020 | 827 | 0.470 |
Why?
| | Ventricular Function, Left | 1 | 2017 | 468 | 0.470 |
Why?
| | Myocarditis | 3 | 2011 | 95 | 0.470 |
Why?
| | Immune Tolerance | 2 | 2019 | 334 | 0.460 |
Why?
| | Simvastatin | 5 | 2022 | 65 | 0.450 |
Why?
| | Receptors, Erythropoietin | 3 | 2018 | 25 | 0.450 |
Why?
| | Myocardial Ischemia | 3 | 2011 | 251 | 0.440 |
Why?
| | Mice, Knockout | 9 | 2017 | 2680 | 0.420 |
Why?
| | Interleukin-6 | 5 | 2022 | 688 | 0.410 |
Why?
| | Erythropoietin | 3 | 2018 | 82 | 0.400 |
Why?
| | Esophagus | 4 | 2020 | 237 | 0.400 |
Why?
| | Spinal Cord | 5 | 2018 | 367 | 0.390 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2022 | 127 | 0.380 |
Why?
| | Cytokines | 7 | 2017 | 1900 | 0.380 |
Why?
| | Mice, Inbred C3H | 6 | 2021 | 250 | 0.370 |
Why?
| | Interleukin-1beta | 2 | 2013 | 379 | 0.370 |
Why?
| | Transfection | 5 | 2017 | 888 | 0.370 |
Why?
| | Gene Knockdown Techniques | 3 | 2017 | 311 | 0.360 |
Why?
| | Case-Control Studies | 5 | 2017 | 3171 | 0.350 |
Why?
| | Lipopeptides | 2 | 2020 | 16 | 0.350 |
Why?
| | Shock, Hemorrhagic | 3 | 2012 | 206 | 0.340 |
Why?
| | Lung Neoplasms | 7 | 2019 | 2220 | 0.340 |
Why?
| | Endotoxins | 1 | 2010 | 234 | 0.340 |
Why?
| | Actins | 3 | 2017 | 404 | 0.330 |
Why?
| | Actin Cytoskeleton | 1 | 2009 | 100 | 0.330 |
Why?
| | Female | 16 | 2022 | 61565 | 0.330 |
Why?
| | Calcium-Binding Proteins | 3 | 2015 | 217 | 0.320 |
Why?
| | Receptors, Cell Surface | 3 | 2004 | 367 | 0.310 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2008 | 374 | 0.300 |
Why?
| | Esophagitis, Peptic | 2 | 2022 | 18 | 0.300 |
Why?
| | Disease Models, Animal | 13 | 2022 | 3730 | 0.300 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 5 | 2018 | 285 | 0.290 |
Why?
| | Phenotype | 7 | 2017 | 3003 | 0.280 |
Why?
| | RNA, Small Interfering | 3 | 2014 | 564 | 0.270 |
Why?
| | Immunoblotting | 3 | 2017 | 307 | 0.270 |
Why?
| | Dexmedetomidine | 3 | 2014 | 52 | 0.260 |
Why?
| | Interleukin-18 | 2 | 2006 | 228 | 0.260 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 4 | 2014 | 968 | 0.250 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 79 | 0.250 |
Why?
| | Ischemia | 2 | 2022 | 374 | 0.250 |
Why?
| | Intercellular Signaling Peptides and Proteins | 3 | 2013 | 369 | 0.240 |
Why?
| | Neuroprotective Agents | 2 | 2018 | 111 | 0.240 |
Why?
| | Biomarkers | 4 | 2022 | 3588 | 0.240 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2017 | 827 | 0.240 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2014 | 29 | 0.230 |
Why?
| | Gene Expression Regulation | 6 | 2017 | 2445 | 0.230 |
Why?
| | Spinal Cord Injuries | 2 | 2018 | 184 | 0.230 |
Why?
| | Jagged-1 Protein | 2 | 2013 | 25 | 0.230 |
Why?
| | Serrate-Jagged Proteins | 2 | 2013 | 30 | 0.230 |
Why?
| | Apoptosis | 5 | 2018 | 2484 | 0.230 |
Why?
| | Fluorescent Antibody Technique | 7 | 2010 | 410 | 0.220 |
Why?
| | Receptors, Interleukin-9 | 1 | 2022 | 4 | 0.220 |
Why?
| | Phosphorylation | 5 | 2013 | 1633 | 0.220 |
Why?
| | MAP Kinase Signaling System | 2 | 2015 | 292 | 0.220 |
Why?
| | Mice, Transgenic | 3 | 2017 | 2025 | 0.220 |
Why?
| | Smad1 Protein | 2 | 2014 | 20 | 0.220 |
Why?
| | Infarction | 1 | 2022 | 16 | 0.220 |
Why?
| | CD18 Antigens | 1 | 2022 | 35 | 0.210 |
Why?
| | Neoplasm Proteins | 2 | 2019 | 401 | 0.210 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 112 | 0.210 |
Why?
| | Heat-Shock Proteins | 2 | 2014 | 129 | 0.200 |
Why?
| | Tumor Burden | 2 | 2020 | 274 | 0.200 |
Why?
| | Diazoxide | 2 | 2018 | 27 | 0.200 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2021 | 37 | 0.200 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 150 | 0.200 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 982 | 0.200 |
Why?
| | Caspases | 1 | 2022 | 269 | 0.200 |
Why?
| | Microglia | 2 | 2013 | 221 | 0.200 |
Why?
| | Pentanoic Acids | 1 | 2020 | 3 | 0.200 |
Why?
| | Inflammasomes | 1 | 2022 | 120 | 0.200 |
Why?
| | Time Factors | 7 | 2014 | 6412 | 0.190 |
Why?
| | Mice, Inbred NOD | 1 | 2022 | 574 | 0.190 |
Why?
| | In Vitro Techniques | 3 | 2009 | 1094 | 0.190 |
Why?
| | Adaptor Proteins, Vesicular Transport | 2 | 2019 | 48 | 0.190 |
Why?
| | Gene Expression | 4 | 2009 | 1489 | 0.190 |
Why?
| | Dinoprostone | 2 | 2019 | 193 | 0.190 |
Why?
| | Indole Alkaloids | 1 | 2020 | 11 | 0.190 |
Why?
| | eIF-2 Kinase | 1 | 2020 | 26 | 0.180 |
Why?
| | Primary Cell Culture | 2 | 2018 | 155 | 0.180 |
Why?
| | Carbazoles | 1 | 2020 | 80 | 0.180 |
Why?
| | STAT3 Transcription Factor | 3 | 2019 | 189 | 0.180 |
Why?
| | Cell Line, Tumor | 9 | 2020 | 2851 | 0.170 |
Why?
| | Blotting, Western | 7 | 2020 | 1194 | 0.170 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 150 | 0.170 |
Why?
| | Matrix Metalloproteinase 12 | 1 | 2018 | 8 | 0.170 |
Why?
| | Cell Movement | 2 | 2014 | 896 | 0.170 |
Why?
| | Cell Adhesion Molecules | 2 | 2021 | 180 | 0.170 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 77 | 0.160 |
Why?
| | Heme Oxygenase-1 | 2 | 2009 | 53 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2020 | 1167 | 0.160 |
Why?
| | Cell Line | 3 | 2020 | 2707 | 0.160 |
Why?
| | Sp7 Transcription Factor | 1 | 2017 | 8 | 0.150 |
Why?
| | Antagomirs | 1 | 2017 | 14 | 0.150 |
Why?
| | Toll-Like Receptors | 2 | 2017 | 167 | 0.150 |
Why?
| | Sclerosis | 1 | 2017 | 14 | 0.150 |
Why?
| | Mice, Mutant Strains | 2 | 2008 | 280 | 0.150 |
Why?
| | Collagen Type III | 1 | 2017 | 20 | 0.150 |
Why?
| | Neutrophils | 6 | 2012 | 1233 | 0.150 |
Why?
| | Poly I-C | 1 | 2017 | 55 | 0.150 |
Why?
| | Calcium | 2 | 2022 | 1169 | 0.150 |
Why?
| | Mice, Inbred Strains | 3 | 2008 | 405 | 0.150 |
Why?
| | NFATC Transcription Factors | 1 | 2017 | 82 | 0.150 |
Why?
| | Membrane Proteins | 2 | 2013 | 1055 | 0.140 |
Why?
| | Collagen Type I | 1 | 2017 | 114 | 0.140 |
Why?
| | Cattle | 2 | 2010 | 978 | 0.140 |
Why?
| | Adult | 10 | 2018 | 31512 | 0.140 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2017 | 148 | 0.140 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1059 | 0.140 |
Why?
| | RNA, Messenger | 8 | 2012 | 2657 | 0.130 |
Why?
| | Molecular Chaperones | 2 | 2014 | 174 | 0.130 |
Why?
| | Protein Kinase C | 1 | 2017 | 297 | 0.130 |
Why?
| | Macrophages | 4 | 2011 | 1324 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 1945 | 0.130 |
Why?
| | Mucous Membrane | 3 | 2010 | 113 | 0.130 |
Why?
| | Smad3 Protein | 1 | 2014 | 47 | 0.130 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 37 | 0.130 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2017 | 151 | 0.130 |
Why?
| | Enzyme Activation | 3 | 2013 | 828 | 0.130 |
Why?
| | Models, Biological | 1 | 2022 | 1715 | 0.120 |
Why?
| | Paraplegia | 2 | 2011 | 60 | 0.120 |
Why?
| | Solubility | 1 | 2014 | 235 | 0.120 |
Why?
| | Microfilament Proteins | 1 | 2014 | 134 | 0.120 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type III | 1 | 2013 | 6 | 0.120 |
Why?
| | Duodenogastric Reflux | 2 | 2010 | 4 | 0.120 |
Why?
| | Calcium Phosphates | 1 | 2013 | 26 | 0.120 |
Why?
| | Mice, Inbred BALB C | 4 | 2010 | 1206 | 0.120 |
Why?
| | Protein Binding | 2 | 2010 | 1975 | 0.120 |
Why?
| | Osteopontin | 2 | 2012 | 39 | 0.120 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2020 | 180 | 0.120 |
Why?
| | Astrocytes | 1 | 2014 | 177 | 0.110 |
Why?
| | Dipeptides | 1 | 2012 | 51 | 0.110 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2012 | 45 | 0.110 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2012 | 76 | 0.100 |
Why?
| | ras Proteins | 1 | 2012 | 141 | 0.100 |
Why?
| | Diiodothyronines | 1 | 2011 | 4 | 0.100 |
Why?
| | Deoxycholic Acid | 2 | 2021 | 20 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2012 | 131 | 0.100 |
Why?
| | Propionates | 1 | 2011 | 35 | 0.100 |
Why?
| | Lung | 5 | 2012 | 3664 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 811 | 0.100 |
Why?
| | Aorta, Abdominal | 1 | 2011 | 40 | 0.100 |
Why?
| | Antibodies, Neutralizing | 2 | 2012 | 228 | 0.100 |
Why?
| | Motor Activity | 2 | 2013 | 660 | 0.100 |
Why?
| | Genetic Therapy | 1 | 2012 | 267 | 0.100 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1974 | 0.100 |
Why?
| | Cardiomyopathies | 1 | 2014 | 299 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 336 | 0.090 |
Why?
| | Ischemic Preconditioning, Myocardial | 1 | 2010 | 31 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2017 | 907 | 0.090 |
Why?
| | Heart Function Tests | 1 | 2010 | 61 | 0.090 |
Why?
| | Antibodies | 2 | 2002 | 392 | 0.090 |
Why?
| | Interleukin-8 | 2 | 2008 | 249 | 0.090 |
Why?
| | A549 Cells | 2 | 2020 | 48 | 0.090 |
Why?
| | Cell Survival | 4 | 2014 | 1047 | 0.090 |
Why?
| | Actinin | 1 | 2009 | 14 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 618 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2012 | 310 | 0.080 |
Why?
| | Polymerization | 1 | 2009 | 129 | 0.080 |
Why?
| | Phospholipases A2 | 1 | 2008 | 77 | 0.080 |
Why?
| | Mutation | 2 | 2012 | 3457 | 0.080 |
Why?
| | Ventricular Pressure | 1 | 2008 | 41 | 0.080 |
Why?
| | Random Allocation | 3 | 2020 | 344 | 0.080 |
Why?
| | beta Catenin | 2 | 2021 | 219 | 0.080 |
Why?
| | Peptidoglycan | 1 | 2007 | 28 | 0.080 |
Why?
| | Myocardial Depressant Factor | 1 | 2007 | 3 | 0.080 |
Why?
| | Perfusion | 1 | 2008 | 153 | 0.080 |
Why?
| | Oxyhemoglobins | 1 | 2007 | 22 | 0.080 |
Why?
| | Lower Extremity | 1 | 2011 | 335 | 0.080 |
Why?
| | Blood Substitutes | 1 | 2007 | 28 | 0.080 |
Why?
| | Pulmonary Valve | 1 | 2009 | 99 | 0.080 |
Why?
| | Kupffer Cells | 1 | 2007 | 47 | 0.080 |
Why?
| | Hyperplasia | 2 | 2010 | 170 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 610 | 0.070 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2007 | 137 | 0.070 |
Why?
| | Hemoglobins | 1 | 2009 | 326 | 0.070 |
Why?
| | Analysis of Variance | 4 | 2012 | 1293 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2008 | 317 | 0.070 |
Why?
| | Caspase 1 | 1 | 2006 | 143 | 0.070 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 823 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 663 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2004 | 36 | 0.060 |
Why?
| | Cell Culture Techniques | 2 | 2019 | 356 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 462 | 0.060 |
Why?
| | Binding Sites | 1 | 2008 | 1224 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 740 | 0.060 |
Why?
| | Glutamine | 1 | 2005 | 88 | 0.060 |
Why?
| | Disease Progression | 2 | 2020 | 2490 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2011 | 968 | 0.060 |
Why?
| | Microscopy, Fluorescence | 2 | 2018 | 412 | 0.060 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 266 | 0.060 |
Why?
| | Immunohistochemistry | 4 | 2009 | 1691 | 0.060 |
Why?
| | DNA | 1 | 2010 | 1388 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2006 | 736 | 0.060 |
Why?
| | Cell Adhesion | 2 | 2020 | 443 | 0.060 |
Why?
| | Vinblastine | 1 | 2002 | 68 | 0.050 |
Why?
| | Leukocyte Elastase | 1 | 2002 | 80 | 0.050 |
Why?
| | Carotid Artery Injuries | 1 | 2002 | 42 | 0.050 |
Why?
| | Tunica Intima | 1 | 2002 | 78 | 0.050 |
Why?
| | Annexin A5 | 1 | 2022 | 24 | 0.050 |
Why?
| | Adenosine Triphosphatases | 1 | 2023 | 158 | 0.050 |
Why?
| | Chemotactic Factors | 1 | 2002 | 51 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2002 | 64 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2014 | 462 | 0.050 |
Why?
| | Peroxidase | 3 | 2012 | 170 | 0.050 |
Why?
| | Growth Substances | 1 | 2002 | 136 | 0.050 |
Why?
| | Cell Count | 1 | 2002 | 315 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2019 | 508 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2011 | 1085 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2002 | 180 | 0.050 |
Why?
| | Caspase 3 | 1 | 2022 | 243 | 0.050 |
Why?
| | Receptors, Interleukin-1 | 1 | 2002 | 228 | 0.050 |
Why?
| | Drosophila Proteins | 1 | 2002 | 171 | 0.050 |
Why?
| | Tissue Banks | 1 | 2020 | 19 | 0.050 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 18 | 0.050 |
Why?
| | Warfarin | 1 | 2021 | 139 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2011 | 2235 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 446 | 0.040 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2018 | 7 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 874 | 0.040 |
Why?
| | Fibrosis | 1 | 2020 | 483 | 0.040 |
Why?
| | Protein Multimerization | 1 | 2019 | 161 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 320 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2019 | 422 | 0.040 |
Why?
| | Brain | 1 | 2009 | 2490 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2020 | 569 | 0.040 |
Why?
| | Sepsis | 1 | 2002 | 531 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 3 | 2009 | 2478 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2012 | 613 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2018 | 344 | 0.030 |
Why?
| | Tensins | 1 | 2014 | 3 | 0.030 |
Why?
| | Aminosalicylic Acids | 1 | 2014 | 7 | 0.030 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 17 | 0.030 |
Why?
| | Benzenesulfonates | 1 | 2014 | 23 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2014 | 173 | 0.030 |
Why?
| | Foscarnet | 1 | 2013 | 19 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1795 | 0.030 |
Why?
| | Nerve Degeneration | 1 | 2013 | 44 | 0.030 |
Why?
| | Minocycline | 1 | 2013 | 28 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2012 | 54 | 0.030 |
Why?
| | Leukotriene C4 | 1 | 2012 | 13 | 0.030 |
Why?
| | Rats | 3 | 2009 | 5392 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2012 | 51 | 0.030 |
Why?
| | Monokines | 2 | 2002 | 26 | 0.030 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2012 | 36 | 0.030 |
Why?
| | Chemokine CXCL2 | 2 | 2002 | 44 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 108 | 0.030 |
Why?
| | Heart Transplantation | 1 | 2018 | 671 | 0.030 |
Why?
| | Eicosanoids | 1 | 2012 | 57 | 0.030 |
Why?
| | Pravastatin | 1 | 2011 | 29 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 160 | 0.030 |
Why?
| | Heptanoic Acids | 1 | 2011 | 62 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 237 | 0.030 |
Why?
| | Radiotherapy | 1 | 2012 | 187 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 290 | 0.020 |
Why?
| | Constriction | 1 | 2011 | 46 | 0.020 |
Why?
| | Culture Media | 1 | 2011 | 163 | 0.020 |
Why?
| | Subclavian Artery | 1 | 2011 | 31 | 0.020 |
Why?
| | Pyrroles | 1 | 2011 | 191 | 0.020 |
Why?
| | Hindlimb | 1 | 2011 | 137 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 316 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 356 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 953 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1223 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 544 | 0.020 |
Why?
| | Organ Specificity | 1 | 2009 | 278 | 0.020 |
Why?
| | Aorta, Thoracic | 1 | 2011 | 248 | 0.020 |
Why?
| | Hypoxia | 1 | 2014 | 963 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 6471 | 0.020 |
Why?
| | Acute Disease | 1 | 2011 | 940 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 380 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 67 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2008 | 190 | 0.020 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2007 | 29 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 324 | 0.020 |
Why?
| | Cell Division | 1 | 2009 | 776 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 9342 | 0.020 |
Why?
| | Probability | 1 | 2008 | 305 | 0.020 |
Why?
| | Age Factors | 1 | 2014 | 2995 | 0.020 |
Why?
| | Prevalence | 1 | 2013 | 2326 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2008 | 160 | 0.020 |
Why?
| | Quercetin | 1 | 2005 | 12 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2006 | 345 | 0.020 |
Why?
| | Lymphocytes | 1 | 2006 | 347 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2010 | 963 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2006 | 442 | 0.010 |
Why?
| | Group IB Phospholipases A2 | 1 | 2002 | 2 | 0.010 |
Why?
| | Receptors, Phospholipase A2 | 1 | 2002 | 2 | 0.010 |
Why?
| | Oxygen | 1 | 2007 | 854 | 0.010 |
Why?
| | Chelating Agents | 1 | 2002 | 74 | 0.010 |
Why?
| | Binding, Competitive | 1 | 2002 | 205 | 0.010 |
Why?
| | Phospholipases A | 1 | 2002 | 101 | 0.010 |
Why?
| | Chemokine CXCL1 | 1 | 2002 | 69 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 2002 | 162 | 0.010 |
Why?
| | Cell Separation | 1 | 2002 | 296 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2011 | 1515 | 0.010 |
Why?
| | Infant | 1 | 2014 | 8293 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2002 | 298 | 0.010 |
Why?
| | Carotid Arteries | 1 | 2002 | 184 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 256 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 316 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 9491 | 0.010 |
Why?
| | Trachea | 1 | 2002 | 226 | 0.010 |
Why?
| | Salmonella typhimurium | 1 | 2002 | 174 | 0.010 |
Why?
| | Risk Factors | 1 | 2013 | 9000 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 384 | 0.010 |
Why?
| | Cell Membrane | 1 | 2002 | 710 | 0.010 |
Why?
| | Escherichia coli | 1 | 2002 | 758 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 10793 | 0.010 |
Why?
| | Adolescent | 1 | 2014 | 18480 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1816 | 0.010 |
Why?
|
|
Meng's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|